Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
43.30
+1.61 (3.86%)
At close: Jan 21, 2026, 4:00 PM EST
43.30
0.00 (0.00%)
After-hours: Jan 21, 2026, 6:09 PM EST
Veracyte Revenue
Veracyte had revenue of $131.87M in the quarter ending September 30, 2025, with 13.82% growth. This brings the company's revenue in the last twelve months to $495.14M, up 16.41% year-over-year. In the year 2024, Veracyte had annual revenue of $445.76M with 23.46% growth.
Revenue (ttm)
$495.14M
Revenue Growth
+16.41%
P/S Ratio
6.58
Revenue / Employee
$600,899
Employees
824
Market Cap
3.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
| Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
| Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
| Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
| Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
| Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
| Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
| Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
| Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
| Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
| Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
| Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
| Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
| Dec 31, 2011 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Charles River Laboratories International | 4.02B |
| RadNet | 1.97B |
| Sotera Health Company | 1.15B |
| Neogen | 880.32M |
| NeoGenomics | 709.16M |
| GeneDx Holdings | 402.19M |
| Twist Bioscience | 376.57M |
| CareDx | 358.00M |
VCYT News
- 5 days ago - Veracyte: Profitable, De-Risked, And Ready To Run - Seeking Alpha
- 6 days ago - Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results - Business Wire
- 23 days ago - Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Veracyte Announces Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing - Business Wire